Prostate Cancer Characteristics and Outcome in Renal Transplant Recipients: Results from a Contemporary Monocentric Study.
1Department of Urology and Transplant surgery, Hôpital Européen Georges Pompidou, AP-HP, Université
Paris Descartes, Paris, France
2Department of Statistics, Computing and Public Health, Hôpital Européen Georges Pompidou, AP-HP, Université
Paris Descartes, Paris, France
3Department of Pathology, Hôpital Necker, AP-HP, Université
Paris Descartes, Paris, France
4Department of Nephrology and Transplantation, Hôpital Necker, AP-HP, Université
Paris Descartes, Paris, France
5Department of Onco-Radiotherapy, Hôpital Necker, AP-HP, Université
Paris Descartes, Paris, France.
Meeting: 2016 American Transplant Congress
Abstract number: D255
Keywords: Kidney transplantation, Malignancy, Outcome, Post-transplant malignancy
Session Information
Session Name: Poster Session D: Poster Session II: Kidney Complications-Other
Session Type: Poster Session
Date: Tuesday, June 14, 2016
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Halls C&D
Objective To analyze prostate cancer characteristics in a contemporary monocentric renal transplant recipients (RTR) population and to compare oncological outcome after radical prostatectomy (RP) with a control population of non-organ transplant patients.
Methods Between 2000 and 2013, 1179 patients received renal transplant. We included all RTR with PCa diagnosed after transplantation. Demographics, PCa characteristics and treatment were assessed. In the RP subset, for each RTR we included the 4 following non-organ transplant patients who underwent RP in our center and compared pre-operative and post-operative oncological features and biochemical recurrence (BCR) rate.
Results Twenty-four RTR (2%) had PCa diagnosis. Median age at diagnosis was 63.5 years. PCa was localized in 21 cases (87.5%) and managed by RP, brachytherapy, radiation therapy and active surveillance in 16 (76.2%), 3 (14.3%), 1(4.7%) and 1(4.7%) cases. Mean follow-up was 44 months. Nineteen RTR with localized PCa (90.5%) were free from BCR. No graft loss was reported. Statistical analysis between RTR (n=16) and control patients (n=64) treated by RP revealed no difference in PCa characteristics at diagnosis, lower Gleason score on prostate specimen in RTR group (p=0.041), but no significant difference for other histological criteria and for BCR rate.
Conclusions Localized PCa following renal transplantation was not associated with adverse features as compared with non-transplant patients. Standard treatments could be proposed to RTR with satisfying results on oncological outcome and graft function.
CITATION INFORMATION: Pettenati C, Jannot A.-S, Verkarre V, Hurel S, Kreis H, Housset M, Legendre C, Méjean A, Timsit M.-O. Prostate Cancer Characteristics and Outcome in Renal Transplant Recipients: Results from a Contemporary Monocentric Study. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:
Pettenati C, Jannot A-S, Verkarre V, Hurel S, Kreis H, Housset M, Legendre C, Méjean A, Timsit M-O. Prostate Cancer Characteristics and Outcome in Renal Transplant Recipients: Results from a Contemporary Monocentric Study. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/prostate-cancer-characteristics-and-outcome-in-renal-transplant-recipients-results-from-a-contemporary-monocentric-study/. Accessed November 22, 2024.« Back to 2016 American Transplant Congress